Janus Henderson Group PLC Verve Therapeutics, Inc. Transaction History
Janus Henderson Group PLC
- $182 Billion
- Q2 2024
A detailed history of Janus Henderson Group PLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 15,031 shares of VERV stock, worth $80,866. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,031
Previous 15,287
1.67%
Holding current value
$80,866
Previous $203,000
64.04%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding VERV
# of Institutions
173Shares Held
74.7MCall Options Held
115KPut Options Held
144K-
Alphabet Inc. Mountain View, CA12.3MShares$66.4 Million3.79% of portfolio
-
Black Rock Inc. New York, NY6.62MShares$35.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$28.3 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.53MShares$24.4 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.87MShares$20.8 Million0.01% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $322M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...